CD274 and non-small cell lung carcinoma: This clinical trial assesses the effectiveness of first-line therapy with tiragolumab plus atezolizumab vs. atezolizumab alone in 534 NSCLC patients with high PD-L1 expression as well as tiragolumab in combination with atezolizumab plus pemetrexed and platinum compound versus pembrolizumab plus platinum-based chemotherapy in 540 NSCLC patients regardless of PD-L1 expression.